Protalix BioTherapeutics
PLX
34 hedge funds and large institutions have $32.9M invested in Protalix BioTherapeutics in 2015 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 9 reducing their positions, and 6 closing their positions.
0.15% less ownership
Funds ownership: 3.11% → 2.96% (-0.15%)
3% less funds holding
Funds holding: 35 → 34 (-1)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
33% less call options, than puts
Call options by funds: $41K | Put options by funds: $61K
33% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 9
42% less capital invested
Capital invested by funds: $56.7M → $32.9M (-$23.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$35.3K |
| 2 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$31.9K |
| 3 |
SIM
Spark Investment Management
New York
|
+$22.4K |
| 4 |
Goldman Sachs
New York
|
+$20.1K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$20K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$1.51M |
| 2 |
Jane Street
New York
|
-$127K |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$99.3K |
| 4 |
NSEDCP
NJ State Employees Deferred Compensation Plan
Trenton,
New Jersey
|
-$78K |
| 5 |
NCCM
Nine Chapters Capital Management
Short Hills,
New Jersey
|
-$68K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Bank of America
Charlotte,
North Carolina
| $4K | – | – | – |
|
27
UBS Group
Zurich,
Switzerland
| $4K | +$4.59K | +289 | +361% |
|
28
Citadel Advisors
Miami,
Florida
| $4K | +$4.71K | +296 | +955% |
|
|
JFA
29
JNBA Financial Advisors
Bloomington,
Minnesota
| $2K | – | – | – |
|
30
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | -$20K | -1,260 | -93% |
|
31
Wells Fargo
San Francisco,
California
| $1K | +$1.11K | +70 | New |
|
32
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $1 | – | – | – |
|
|
NSEDCP
33
NJ State Employees Deferred Compensation Plan
Trenton,
New Jersey
| – | -$78K | -4,000 | Closed |
|
|
NCCM
34
Nine Chapters Capital Management
Short Hills,
New Jersey
| – | -$68K | -3,510 | Closed |
|
35
Group One Trading
Chicago,
Illinois
| – | -$20.2K | -1,272 | Closed |
|
36
Two Sigma Advisers
New York
| – | -$20K | -1,030 | Closed |
|
|
OAM
37
Oxford Asset Management
Oxford,
United Kingdom
| – | -$20K | -1,017 | Closed |
|
38
Simplex Trading
Chicago,
Illinois
| – | -$12.5K | -785 | Closed |
|
39
Credit Agricole
Montrouge Cedex,
France
| – | +$64 | +4 | New |
|
PLX Hedge Fund Activity: Q3 2015 in Review
34 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q3 2015, worth a combined $32.9M — down 42% from $56.7M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of PLX and 5 opened new positions — a net loss of 1 holder — while 9 trimmed existing stakes and 6 added.
The largest buyer was Bridgeway Capital Management, adding an estimated $35.3K. The largest seller was Federated Hermes, cutting an estimated $1.51M.
- 34 institutional investors held Protalix BioTherapeutics (PLX) as of Q3 2015, down from 35 in Q2 2015.
- Funds reported $32.9M of Protalix BioTherapeutics stock for Q3 2015, down 42% quarter-over-quarter.
- 5 funds opened new Protalix BioTherapeutics positions in Q3 2015 and 6 closed out, a net change of -1 holder.
- The largest Protalix BioTherapeutics buyer in Q3 2015 was Bridgeway Capital Management, an estimated $35.3K added.
- The largest Protalix BioTherapeutics seller in Q3 2015 was Federated Hermes, an estimated $1.51M sold.
Based on aggregated 13F filings for Q3 2015.